WEBULL
WebtradeDownload

Medibank (ASX:MPL) Shares Look Past Claims Risk As Margins Strengthen

Simply Wall St · 2d ago

Medibank Private has come into this result with a flat to softer share price over the past month, yet the latest earnings show a business quietly tightening its grip on profitability. The stock closed at A$4.95 on 21 August after a modest 30 day slide, while full year operating profit reached A$813.5m and underlying earnings per share moved to A$0.231. The real story is margin quality. Net profit margin over the past year sat at 6.9% and Medibank Health segment profit jumped 31.3%, which is where sentiment and fundamentals now collide.

Is Medibank Private trading at a rare 30% discount to fair value, or are its 21.3x P/E and slower forecast growth already fair? Compare the current price against our detailed valuation analysis for Medibank Private

FY 2026 Earnings Summary

  • Revenue (FY 2026 vs FY 2025 PCP): A$9,294.1m vs A$8,556.3m (up 8.6%)
  • Net Income (Excl. Extra Items, FY 2026 vs FY 2025 PCP): A$638.7m vs A$500.8m (up 27.5%)
  • Basic EPS (Earnings Per Share, FY 2026 vs FY 2025 PCP): A$0.232 vs A$0.181844 (up 27.5%)
  • Net Profit Margin (FY 2026 vs FY 2025 PCP): 6.9% vs 5.9% (improved by 1.0 percentage point)

Prefer clear visuals instead of scrolling through pages of earnings tables and PDFs? Get a full visual breakdown of Medibank Private with an at a glance view of its valuation picture in the company report for Medibank Private.

ASX:MPL Trailing 12-Month Earnings & Revenue History as at Aug 2026
ASX:MPL Trailing 12-Month Earnings & Revenue History as at Aug 2026

Medibank bullish story: margins and health pivot tested

Bulls argue Medibank is quietly building a higher quality insurer that uses health services and digital tools to protect margins. The latest year gives them some concrete wins. Group operating profit reached A$813.5m and underlying EPS was A$0.231, with resident gross margin described as stable at 17% and resident gross margin per policy unit at 16.3% with a small uplift. Expense ratio stayed near 8% and operating margin around 9%, which aligns with the thesis of tighter cost control rather than volume chasing. Medibank Health is key to the diversification claim. Segment profit rose to A$100.7m, up 31.3%, on revenue growth of 30.8%. Management also points to 57% of Medibank policyholders now using health and wellbeing offerings, which supports the idea that care delivery and engagement are moving from side project to meaningful business line.

Medibank bear story: claims, churn and regulatory drag

The bear story focuses on affordability pressure, claims inflation and regulatory drag eating into Medibank’s earnings power. There are some early warning signs. Resident claims per policy unit rose 2.6%. Management also flagged that a A$74.8m COVID related utilization benefit will not repeat, which they estimate will lift hospital claims growth per policy unit from about 2.1% to about 3.6% in FY27. That directly touches the fear that claims inflation can outrun premium increases. Nonresident policy units fell 2.3%, which supports concerns about pressure in more discretionary segments, even though worker policies are described as growing. The continued APRA cyber supervisory adjustment and litigation costs into FY27 keep the regulatory and cyber overhang alive. Removing AHM from an aggregator panel shows discipline on commissions, yet it also confirms that acquisition costs and competitive intensity remain a real friction point.

Reveal where the surface looks calm, but the models start to disagree on Medibank Private's next few reporting seasons. Access the analyst estimates for Medibank Private.

Stay Ahead Of Your Next Move

If Medibank Private's margin story and health segment shift have you interested, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a better entry point. Once you own shares, use the Portfolio Command Center to cut through noise and focus on the key developments that matter to your holdings. For a longer term view, tap into crowd wisdom through the Community and see how other investors are thinking about Medibank Private. By surfacing potential catalysts and risks early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Medibank Private

Fresh ideas can move fast. Some stocks are building quiet momentum while others are dropping back under the radar for now. Check these curated lists and review them while they are still timely.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.